aid: adlai-nortye
name: Adlai Nortye
description: >-
  Adlai Nortye is a global clinical-stage biopharmaceutical company, headquartered in
  Hangzhou, China with US operations in New Jersey, developing differentiated
  immuno-oncology and precision-targeted cancer medicines. Its pipeline covers two
  therapeutic areas: precision RAS pathway targeted therapies — the oral pan-RAS(ON)
  inhibitor AN9025 and the CEACAM5-targeting antibody-drug conjugate AN4035 built on the
  company's proprietary RASiCA (RAS Inhibitor Conjugated Antibody) platform — and
  next-generation PD-1/L1 pathway modulating immunotherapies including AN8025, a
  multi-functional T-cell and antigen-presenting-cell modulating fusion protein, plus the
  oral EP4 antagonist AN0025 (palupiprant). The company is listed on Nasdaq under the
  ticker ANL. Adlai Nortye publishes no developer program, API, SDK or machine-readable
  contract of any kind.
image: https://www.adlainortye.com/static/web/img/logob_20210415.svg
url: https://raw.githubusercontent.com/api-evangelist/adlai-nortye/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-07'
modified: '2026-09-07'
position: Producing
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Healthcare
- Oncology
- Clinical Trials
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/adlai-nortye-domain-security.yml
- type: Website
  url: https://www.adlainortye.com/
- type: About
  url: https://www.adlainortye.com/index.php/about
- type: x-DrugPipeline
  url: https://www.adlainortye.com/index.php/products
- type: PressReleases
  url: https://www.adlainortye.com/index.php/news
- type: Support
  url: https://www.adlainortye.com/index.php/contact
- type: TermsOfService
  url: https://www.adlainortye.com/index.php/termOfUse
- type: PrivacyPolicy
  url: https://www.adlainortye.com/index.php/privacyPolicy
- type: Careers
  url: https://www.adlainortye.com/index.php/recruit
- type: Partners
  url: https://www.adlainortye.com/index.php/partner_business
- type: LinkedIn
  url: https://www.linkedin.com/company/adlainortye/
- type: Twitter
  url: https://x.com/AdlaiNortyeBio
- type: x-SecondaryMarket
  url: https://forgeglobal.com/adlai-nortye_stock/
- type: LLMsTxt
  url: llms/adlai-nortye-llms.txt
x-enrichment:
  date: '2026-09-07'
  status: minimal
  artifacts_added: 3
  pass: local-v3
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Adlai Nortye is a clinical-stage oncology drug developer (Nasdaq: ANL) whose product is
    a molecule, not software - its corporate site has no developer, docs or API section at
    all, and every contract probe across www, ir and cn returned 403 or 404.
  evidence:
  - url: https://www.adlainortye.com/openapi.json
    status: 404
  - url: https://www.adlainortye.com/llms.txt
    status: 404
  - url: https://www.adlainortye.com/.well-known/agent-card.json
    status: 403
  - url: https://www.adlainortye.com/apis.json
    status: 404
  - url: https://ir.adlainortye.com/
    status: 403
  checked: '2026-09-07'